Abstract: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk for several adverse outcomes among patients with diabetic kidney disease. Yet, optimal timing for …
Abstract: BACKGROUND: The effect of SGLT2i on kidney function after acute kidney injury (AKI) is unknown. METHODS: The study population was drawn from a retrospective cohort of …
Abstract: BACKGROUND: Patients with chronic kidney disease (CKD) are at increased risk for multiple adverse events, several of which have been proven to be less likely with the use …
Abstract: Significance Statement: Among patients with CKD, optimal use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after AKI is uncertain. …